ARGX vs. BMY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and BMY, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
BMY stands out with 95.26 billion USD in market value—about 2.67× ARGX’s market cap of 35.72 billion USD.
BMY carries a higher beta at 0.40, indicating it’s more sensitive to market moves, while ARGX remains steadier at 0.17.
ARGX trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while BMY remains a standard domestic listing.
| Symbol | ARGX | BMY |
|---|---|---|
| Company Name | argenx SE | Bristol-Myers Squibb Company |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Dr. Christopher S. Boerner Ph.D. |
| Price | 584.95 USD | 46.81 USD |
| Market Cap | 35.72 billion USD | 95.26 billion USD |
| Beta | 0.17 | 0.40 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 18, 2017 | June 1, 1972 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of ARGX and BMY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ARGX and BMY based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- BMY shows a negative forward PEG of -3.01, signaling expected earnings contraction, while ARGX at 1.35 maintains analysts’ projections for stable or improved profits.
- ARGX has a negative Price-to-Free Cash Flow ratio of -455.63, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, BMY (P/FCF 7.28) indicates positive free cash flow generation.
| Symbol | ARGX | BMY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 51.04 | 17.54 |
| Forward PEG Ratio (TTM) | 1.35 | -3.01 |
| Price-to-Sales Ratio (P/S, TTM) | 16.49 | 2.00 |
| Price-to-Book Ratio (P/B, TTM) | 7.74 | 5.47 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -455.63 | 7.28 |
| EV-to-EBITDA (TTM) | 4569.26 | 8.38 |
| EV-to-Sales (TTM) | 15.83 | 2.85 |
| EV-to-Free Cash Flow (TTM) | -437.47 | 10.36 |
Dividend Comparison
ARGX offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while BMY provides a 5.21% dividend yield, giving investors a steady income stream.
| Symbol | ARGX | BMY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 5.21% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ARGX and BMY, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- With negative EBIT (-20.85), ARGX cannot cover its interest payments. BMY, with an interest coverage of 4.36, meets its interest obligations.
| Symbol | ARGX | BMY |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 1.28 |
| Quick Ratio (TTM) | 6.68 | 1.17 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 2.95 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.55 |
| Interest Coverage Ratio (TTM) | -20.85 | 4.36 |